- Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPC.
- Ryan C.
- OncLive. 2022 Oct 3.
- News
- Free Full Text
Identifier: NCT02975934: A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3). (ClinicalTrials.gov . Accessed 2022 Oct 5.)